Investor Relations
Overview
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.
Events & Presentations
SEC Filings
Investor Contacts
Michael Booth D.Phil
Divisional VP of Investor Relations and Corporate Social Responsibility
Phone: 302.498.5914
E-mail: mbooth@incyte.com
Lauren Ayala
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: layala@incyte.com
Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536
